Literature DB >> 7763285

Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil.

S Copur1, K Aiba, J C Drake, C J Allegra, E Chu.   

Abstract

A series of 5-fluorouracil (5-FU)-resistant human colon H630 cancer cell lines were established by continuous exposure of cells to 5-FU. The concentration of 5-FU required to inhibit cell proliferation by 50% (IC50) in the parent colon line (H630) was 5.5 microM. The 5-FU IC50 values for the resistant H630-R1, H630-R10, and H630-R cell lines were 11-, 29-, and 27-fold higher than that for the parent H630 cell line. Using both the radioenzymatic 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP) binding and catalytic assays for measurement of thymidylate synthase (TS) enzyme activity, there was significantly increased TS activity in resistant H630-R1 (13- and 23-fold), H630-R10 (37- and 40-fold), and H630-R (24- and 34-fold) lines, for binding and catalytic assays, respectively, compared with the parent H630 line. The level of TS protein, as determined by western immunoblot analysis, was increased markedly in resistant H630-R1 (23-fold), H630-R10 (33-fold), and H630-R (26-fold) cells. Northern analysis revealed elevations in TS mRNA levels in H630-R1 (18-fold), H630-R10 (39-fold), and H630-R (36-fold) cells relative to parent H630 cells. Although no major rearrangements of the TS gene were noted by Southern analysis, there was significant amplification of the TS gene in 5-FU-resistant cells, which was confirmed by DNA slot blot analysis. These studies demonstrate that continuous exposure of human colon cancer cells to 5-FU leads to TS gene amplification and overexpression of TS protein with resultant development of fluoropyrimidine resistance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7763285     DOI: 10.1016/0006-2952(95)00067-a

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  44 in total

1.  Transcriptomic classification of antitumor agents: application to the analysis of the antitumoral effect of SR31747A.

Authors:  Jean-Bernard Ferrini; Omar Jbilo; Annick Peleraux; Therese Combes; Hubert Vidal; Sylvaine Galiegue; Pierre Casellas
Journal:  Gene Expr       Date:  2003

2.  A pilot study evaluating the safety and toxicity of epirubicin, cisplatin, and UFT (ECU regimen) in advanced gastric carcinoma.

Authors:  Sezer Saglam; N Faruk Aykan; Burak Sakar; Mine Gulluoglu; Emre Balik; Hasan Karanlik
Journal:  J Gastrointest Oncol       Date:  2011-03

3.  Identification of in vivo target RNA sequences bound by thymidylate synthase.

Authors:  E Chu; T Cogliati; S M Copur; A Borre; D M Voeller; C J Allegra; S Segal
Journal:  Nucleic Acids Res       Date:  1996-08-15       Impact factor: 16.971

4.  Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.

Authors:  Marta Geretto; Alessandra Pulliero; Camillo Rosano; Dinara Zhabayeva; Rakhmet Bersimbaev; Alberto Izzotti
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

5.  Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up.

Authors:  Silke Lassmann; Michael Hennig; Robert Rosenberg; Jörg Nährig; Joachim Schreglmann; Friedemann Krause; Manuela Poignee-Heger; Hjalmar Nekarda; Heinz Höfler; Martin Werner
Journal:  Int J Colorectal Dis       Date:  2005-08-13       Impact factor: 2.571

6.  A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.

Authors:  Marwan G Fakih; Gerald Fetterly; Merrill J Egorin; Josephia R Muindi; Igor Espinoza-Delgado; James A Zwiebel; Alan Litwin; Julianne L Holleran; Kangsheng Wang; Robert B Diasio
Journal:  Clin Cancer Res       Date:  2010-05-12       Impact factor: 12.531

7.  Activation of Two Sequential H-transfers in the Thymidylate Synthase Catalyzed Reaction.

Authors:  Zahidul Islam; Timothy S Strutzenberg; Ananda K Ghosh; Amnon Kohen
Journal:  ACS Catal       Date:  2015-09-02       Impact factor: 13.084

8.  In-vivo evaluation in rats of colon-specific microspheres containing 5-fluorouracil.

Authors:  Ziyaur Rahman; Kanchan Kohli; Shuang-Qing Zhang; Roop K Khar; Mushir Ali; Naseem A Charoo; Mohammad Tauseef; Areeg A A Shamsher; Noorullah N Mohammed; Michael A Repka
Journal:  J Pharm Pharmacol       Date:  2008-05       Impact factor: 3.765

Review 9.  Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature.

Authors:  B Klump; O Nehls; T Okech; C-J Hsieh; V Gaco; F S Gittinger; M Sarbia; F Borchard; A Greschniok; H H Gruenagel; R Porschen; M Gregor
Journal:  Int J Colorectal Dis       Date:  2003-06-21       Impact factor: 2.571

10.  Mucinous and non-mucinous colorectal cancers show differential expression of chemotherapy metabolism and resistance genes.

Authors:  J P Burke; J H M Prehn; E O'Connell; I S Reynolds; M Salvucci; D A McNamara
Journal:  Pharmacogenomics J       Date:  2021-03-17       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.